Isogaine (Mepivacaine Hydrochloride)

Mepivacaine Hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium ions needed for depolarisation. This reversible blockade stops the transmission of nerve impulses, resulting in a localized anaesthetic effect at the injection site.

The appropriate dose of Isogaine is determined by the prescribing clinician based on the type of procedure, patient age, weight, and clinical condition. Dosage guidelines are provided in the product’s prescribing information and should be followed strictly by qualified healthcare professionals.

Safety data for Mepivacaine Hydrochloride during pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and only under professional medical supervision.

To request Isogaine, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Both Isogaine (Mepivacaine) and lidocaine are amide‑type local anesthetics, but Mepivacaine typically has a slightly longer duration of action and a lower propensity for vasodilation, often allowing use without added vasoconstrictors. Choice depends on the clinical setting, desired duration, and patient‑specific factors.

Isogaine should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

Isogaine is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via intramuscular or subcutaneous injection. The injection site is selected based on the required area of anesthesia, and aspiration is recommended before injection to avoid intravascular delivery.

Serious risks include allergic reactions such as anaphylaxis, cardiac arrhythmias or conduction disturbances, and central nervous system toxicity that may manifest as seizures or severe hypotension. Immediate medical attention is required if any of these symptoms occur.

Isogaine should be avoided in patients with a known hypersensitivity to Mepivacaine, other amide‑type local anesthetics, or any of the product’s excipients. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or when intravascular injection cannot be reliably excluded.